Bcirg PowerPoint PPT Presentations
All Time
Recommended
Title: BCIRG Author: Jim Mortimer Last modified by: Administrator Created Date: 6/20/2000 11:05:45 AM Document presentation format: On-screen Show Company
| PowerPoint PPT presentation | free to download
Title: Overcoming Resistance to HER2-Targeted Therapy in Patients With Advanced Breast Cancer Author: SOluku Last modified by: IMGTemp Created Date
| PowerPoint PPT presentation | free to download
Role of Hematopoietic Growth Factors in the Prevention of Neutropenic Complications for Breast Cancer Patients Treated with Docetaxel, Doxorubicin, and ...
| PowerPoint PPT presentation | free to download
Roch H et al J Clin Oncol 2006. PACS-01: DFS in different subgroups (Forest plot analysis) ... Roch H et al J Clin Oncol 2006. ECTO Study. Gianni L, et al, ...
| PowerPoint PPT presentation | free to view
The incidence of cardiac events reach a plateau at around 1 year ... survival, time to recurrence, and time to ... NOAH study: neoadjuvant Herceptin for LABC ...
| PowerPoint PPT presentation | free to view
Title: Presentazione di PowerPoint Author: Oncologia Last modified by: Oncologia Created Date: 10/21/2006 12:05:09 PM Document presentation format
| PowerPoint PPT presentation | free to view
... (r gression logistique) L effet du traitement doit tre significatif sur le crit re final (mod le de Cox) L effet du crit re interm diaire doit tre ...
| PowerPoint PPT presentation | free to download
Title: Bioestad stica y dise o de ensayos cl nicos Author: USO Last modified by: KIKO Created Date: 1/29/2005 4:18:12 PM Document presentation format
| PowerPoint PPT presentation | free to download
Leads to inefficient and potentially toxic treatment for many to ... Prophylactic Cipro 500 mg bid, day 5-14. Every 3 weeks x 6 cycles. Stratification: Nodes: ...
| PowerPoint PPT presentation | free to view
Les th rapeutiques cibl es dans le cancer du sein Mythes ou r alit s ? Dr. Thomas Bachelot Centre L on B rard, Lyon
| PowerPoint PPT presentation | free to download
Title: PowerPoint Presentation Last modified by: jchung Document presentation format: On-screen Show Other titles: Times New Roman Verdana Marlett Arial Symbol Times ...
| PowerPoint PPT presentation | free to download
La chemioterapia adiuvante Lucia Del Mastro Istituto Naz. per la Ricerca sul Cancro - Genova Roma 18 Febbraio 2005 Adjuvant chemotherapy The present Anthracyclines ...
| PowerPoint PPT presentation | free to view
HER2-neu (human epidermal growth factor receptor 2) ... Ventana PATHWAYTM HER-2: automated staining system ~2300000 ~500000 ~100000 ...
| PowerPoint PPT presentation | free to view
Discussion Topics HER2 positive disease Growing number of options Angiogenesis Bevacizumab questions answered and rephrased Small molecule success and ...
| PowerPoint PPT presentation | free to download
... be confirmed in the other central lab Central Laboratory HER2 % local false-positive ER % discordant IEO 14.5% of 8,037 12.1% of 9,021 Mayo Clinic 5.8% of ...
| PowerPoint PPT presentation | free to download
CONGRESO CHILENO DE CANCEROLOGIA TERAPIAS BIOLOGICAS DIRIGIDAS EN CANCER DE MAMA Dr. Jorge Luis Soriano Garc a Ph.D. Jefe Servicio de Oncolog a Cl nica
| PowerPoint PPT presentation | free to view
adjuvant treatment with trastuzumab. AGO Organkommission 'Mamma' as of July 19th, 2005 ... Adjuvant treatment with trastuzumab in primary breast cancer patients ...
| PowerPoint PPT presentation | free to view
... it expects an ultimate enrollment of 8,000 patients Co-amplification of c-myc and HER2: benefit of trastuzumab Co-amplification of c-myc and HER2: ...
| PowerPoint PPT presentation | free to view
Current Patterns of Care: Case C a 55 yo with a 2.4-cm, Grade II, ER/PR ... Oak Lawn, Illinois ... 12:05 PM Dr Love: Current patterns of care in the community ...
| PowerPoint PPT presentation | free to download
pathophysiology of HER-2 family of proteins. diagnostic testing ... Paclitaxel for patients who had received adjuvant anthracycline. R. A. N. D. O. M. I. Z. E ...
| PowerPoint PPT presentation | free to view
(Neo-)adjuvante systemische therapie. Een goed begin... Marijke Bontenbal ... RHEA. Relapse. Surgery. 2nd lines. NOAH. MDACC. GeparQuattro. Numerous Phase II studies ...
| PowerPoint PPT presentation | free to view
RAK DOJKE MLA IH ENA ODABIR LIJE ENJA I PLODNOST Zdenko Krajina Centar za ekspertnu medicinu, Zagreb
| PowerPoint PPT presentation | free to download
Overexpressed in 25 to 30% of breast cancers ... Anaphylaxis/pulmonary events. Glomerulopathy. Monotherapy. 9.1M. 15% Prior chemo. Cobleigh MA et al ...
| PowerPoint PPT presentation | free to view
Cancer Research. Historical Note ... To accelerate the pace of clinical cancer research. ... Cancer Research. Historical Note. New features of the system: ...
| PowerPoint PPT presentation | free to view
Mammogram. Balance the need for diagnostic workup and avoid unnecessary procedure(s) ... Diagnostic mammogram. Reserved for older than 30 years of age ...
| PowerPoint PPT presentation | free to view
CARCINOMA DELLA MAMMELLA The Aromatase Inhibitor Trials ATAC: Tamoxifen vs Anastrozole vs Combined therapy MA17 : Letrozole vs placebo after 5yr Tamoxifen IES ...
| PowerPoint PPT presentation | free to download
HER-2 targeting: dalla malattia avanzata alla fase pre-operatoria Marco Venturini Roma, Febbraio 2005 Tailored Treatment of HER2+ MBC Trastuzumab + Taxanes ...
| PowerPoint PPT presentation | free to view
tudes sur les s quences et les alternances. tudes de dose: intensification th rapeutique, ... Dans les essais, l' adjonction du taxane ou sa substitution un autre cytotoxique ...
| PowerPoint PPT presentation | free to view
The latest in treatments, testing. and clinical trials. Dr Michael Untch. Breast Cancer Service, ... lung, breast, prostate and colon. It may sensitize tumour ...
| PowerPoint PPT presentation | free to view
A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer ... Survival with adjuvant surgical oophorectomy and tamoxifen in premenopausal ...
| PowerPoint PPT presentation | free to view
Needle biopsy showed invasive ductal carcinoma, grade III/III with ductal ... (Central FISH) N or high. risk N- 4 x AC. 60/600 mg/m2. 4 x Docetaxel. 100 mg/m2 ...
| PowerPoint PPT presentation | free to view
Angiogenesis: Using Old and New Approaches John Mackey, MD Professor of Oncology University of Alberta Edmonton, Canada Preconditions for a VEGF Pathway Predictive ...
| PowerPoint PPT presentation | free to view
in women with HER-2 positive primary breast cancer who have completed adjuvant chemotherapy ... Nodal status, adjuvant CT regimen, hormone receptor status and ...
| PowerPoint PPT presentation | free to download
